MorphoSys's AbD Serotec Expands Antibody License Agreement with Medical Research Council
Advertisement
MorphoSys AG announced that its business unit AbD Serotec has significantly expanded its license agreement with MRC Technology (MRCT), the technology transfer arm of Great Britain's Medical Research Council (MRC). The agreement, which provides AbD Serotec with access to a broad range of hybridoma cell lines as a source of research antibodies, is extended for a further five years, and includes additional products which will be implemented in AbD Serotec's offering. Financial details of the agreement were not disclosed.
"Our long-lasting relationship with the Medical Research Council as a source of research antibodies has led to a large number of innovative products for our costumers," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG. "Sales on all products from this license agreement are of significant value for AbD Serotec, and to be able to continue this long-term relationship with one of the most influential research organizations in Great Britain is thus of significant value for the entire MorphoSys Group."
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents
BGU researchers develop new fast test to tell bacterial and viral infections apart - Prof. Robert Marks and multi-disciplinary team tracked the immune system’s response to infection
Cellomics and GE Healthcare Collaborate To Provide Faster and More Effective Cellular Screening - Software Development and Commercialization Agreement Offers Informatics Solution for High Content Screening
NeuroVive and to-BBB awarded Eurostars grant for development of stroke therapy
Oxford Nanopore Announces Licence Agreement with Harvard University for Graphene DNA sequencing
to-BBB starts manufacturing collaboration with TTY Biopharm for brain cancer treatment
HealthLinx and InSymbiosis to co-develop therapeutic for lung disease
TxCell achieves positive results for Col-Treg in a model of autoimmune uveitis
Genomatix Wins BioChance Grant for $1.6 Mio Research Project into RNAi Mediated Regulatory Networks
Clearbridge BioMedics makes a big impact at the 2012 Asian Innovation Awards
Kansas State University professor's USDA research shows mad cow disease also caused by genetic mutation
BASF applies for European approval for Fortuna, a disease-resistant table potato
